Aim is to have one candidate based on bi-specific antibody technology in preclinical studies early next year.
Oncobiologics and Fox Chase Cancer Center are teaming up to develop a next-generation bi-specific antibody cancer platform for solid tumors. Preclinical studies for the first molecule using this platform are expected in the first quarter of 2012.
The platform integrates intellectual property originated by both Oncobiologics and Fox Chase. Oncobiologics will play a role in the discovery program that will be carried out at Fox Chase, and will use its platform to develop therapeutic products and move them through clinical trials. The two organizations expect to partner out commercialization of drug candidates and are also seeking co-development partners.
Matt Robinson, Ph.D., principal investigator at Fox Chase, and John Cini, Ph.D., vp at Oncobiologics, comment, “We believe this platform can improve cancer therapies by improving tumor delivery, enhancing pharmacokinetics, and providing the opportunity for synergistic bi-specific antibody delivery.”